As shown in Figures 2A–F and Supplementary Figure S2, the expression level of SPARCL1 was elevated as the pathological stages of BLCA, KIRP, and STAD increased while low expression of SPARCL1 increased the likelihood of low pathological stages in BRCA, KIRC, and THCA. Here, SPARCL1 is linked to bladder transitional cell carcinoma.